艾司西酞普兰治疗社交焦虑障碍：随机、安慰剂对照、灵活剂量研究。
Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study.
作者信息
Kasper Siegfried, Stein Dan J, Loft Henrik, Nil Rico
机构信息
Department of General Psychiatry, University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
出版信息
Br J Psychiatry. 2005 Mar;186:222-6. doi: 10.1192/bjp.186.3.222.
BACKGROUND
Selective serotonin reuptake inhibitors are effective in the treatment of social anxiety disorder and are currently regarded as the pharmacotherapy of choice.
AIMS
To investigate the efficacy and tolerability of escitalopram in the treatment of generalised social anxiety disorder.
METHOD
Patients with generalised social anxiety disorder were randomised to receive placebo (n=177) or 10-20 mg escitalopram (n=181) in a 12-week, double-blind trial. The primary outcome measure was the mean change from baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) total score.
RESULTS
The study showed a statistically superior therapeutic effect for escitalopram compared with placebo on the LSAS total score (P=0.005). There were significantly more responders to treatment for escitalopram than for placebo (54% v. 39%; P<0.01). The clinical relevance of these findings was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment.
CONCLUSIONS
Escitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder.
背景
选择性5-羟色胺再摄取抑制剂对社交焦虑障碍有效，目前被视为首选药物治疗方法。
目的
调查艾司西酞普兰治疗广泛性社交焦虑障碍的疗效和耐受性。
方法
在一项为期12周的双盲试验中，将广泛性社交焦虑障碍患者随机分为两组，分别接受安慰剂治疗（n = 177）或10 - 20毫克艾司西酞普兰治疗（n = 181）。主要疗效指标是利博维茨社交焦虑量表（LSAS）总分从基线到最后评估的平均变化。
结果
研究表明，与安慰剂相比，艾司西酞普兰在LSAS总分上具有统计学上更优的治疗效果（P = 0.005）。接受艾司西酞普兰治疗的有效应答者显著多于接受安慰剂治疗的患者（54%对39%；P < 0.01）。希恩残疾量表工作和社交部分的显著降低以及艾司西酞普兰治疗的良好耐受性支持了这些发现的临床相关性。
结论
艾司西酞普兰在治疗广泛性社交焦虑障碍方面有效且耐受性良好。
Zotero 插件